Clinical Observation of Gemcitabine Combined With Cisplatin Versus Docetaxel Combined With Cisplatin in the Treatment for Patients with Advanced NSCLC

Objective To compare the efficacy of gemcitabine combined with cisplatin versus docetaxel combined with cisplatin in advanced non-small cell lung cancer(NSCLC),respectively.Methods A total of 72 patients with advanced NSCLC were randomized into two groups:one group were treated with gemcitabine and cisplatin,and the other group was treated with decetaxel and cisplatin.Each patient received 2 cycles' chemotherapy at least.The short-term effect,side effects,median survival time and 1-year survival rate were evaluated after chemotherapy.Results The short-term response rates in gemcitabine combined with cisplatin versus docetaxel combined with cisplatin were 47.2%and 44.5%respectively,1-year survival rates were 44.5%and 41.7%,and the median survival time was 11.4 months and 11.1 months respectively.No significant difference was observed between the two groups(P0.05).Conclusion Regimens of gemcitabine combined with cisplatin and docetaxel combined with cisplatin are both safe and effective in the treatment of advanced NSCLC.They can be used as the first regimen of chemotherapy in patients with advanced NSCLC.